STSS

Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems

Retrieved on: 
Friday, February 16, 2024
Diabetes, STSS, Needle, Weight loss, Infection, Syringe, Inflammation, Vaccine, CDMO, Safety, World Health Organization, Roncadelle, Disease, Partnership

Sharps Technology specializes in the development and manufacturing of innovative drug delivery systems.

Key Points: 
  • Sharps Technology specializes in the development and manufacturing of innovative drug delivery systems.
  • These features protect frontline healthcare workers from life-threatening needle stick injuries and protect the public from the dangers of needle re-use.
  • Their SafeR Retractable Safety Syringe and needles offer a passive safety system with auto-disable reuse prevention features.
  • Additionally, as a Contract Development and Manufacturing Organization (CDMO), they also provide end-to-end services from design to finished products of innovative, safer medical drug delivery solutions.

VIA Names Tremell Brown Deputy Chief Executive Officer

Retrieved on: 
Tuesday, May 23, 2023
Transport, Public Transport, Entrepreneurship, Human resources, Public Transport Corporation, University, Life, Incident, Law enforcement, Northside Independent School District, Lead, Emergency management, Innovation, Multimedia, STSS, Institute for Veterans and Military Families, Billy Tremelling, University of the Incarnate Word, School, Northside, Lackland Air Force Base, Organization, VIA Metropolitan Transit, Armed Forces Special Operations Division, Operations Division (Royal Navy), DCEO, Management, VIA, Safety

2 leadership position, selecting Tremell Brown, a 33-year veteran of the agency, to serve as Deputy CEO.

Key Points: 
  • 2 leadership position, selecting Tremell Brown, a 33-year veteran of the agency, to serve as Deputy CEO.
  • He advanced through the Operations Division, having held several leadership positions, including Vice President of Transportation, VP of Safety, Training and System Security and Chief Safety Officer.
  • As DCEO, Brown will assist VIA’s President/CEO in oversight of all staff functions and agency operations.
  • “During his tenure at VIA, Tremell has served with distinction and accumulated invaluable experience across the agency,” President/CEO Jeffrey C. Arndt said.

BridgeComm Names Rich Tortorelli as Chief Systems Engineer

Retrieved on: 
Thursday, February 10, 2022
Technology, Satellite, Mobile, Wireless, Telecommunications, Networks, Internet, Lockheed, Veteran, NASA, STSS, Government, Missile Defense Agency, United States Secretary of the Air Force, Atmosphere, Solution, OWC, RF, Leadership, OWS, Communication, Engineering, Knowledge, Growth, General Atomics, Program, Intelligence, Loyola, Avenger, ASAT, Communications satellite

BridgeComm, Inc. , a leader in optical wireless communications (OWC) solutions and services, today announced that Rich Tortorelli will join the company as a chief systems engineer.

Key Points: 
  • BridgeComm, Inc. , a leader in optical wireless communications (OWC) solutions and services, today announced that Rich Tortorelli will join the company as a chief systems engineer.
  • Having developed, managed and executed 160 plus satellites with space-based constellations, Tortorelli brings thirty years of invaluable experience to BridgeComm to enhance its OWS space produce development efforts.
  • Prior to BridgeComm, Tortorelli served as the chief systems engineer at General Atomics, where he oversaw a NASA program, mentored and led a technical staff of 50 individuals and was responsible for systems end-to-end architecture, integration, testing, verification, launch and deployment, among many other responsibilities.
  • Tortorelli has worked for a variety of satellite companies developing and delivering satellites to customers such as the Missile Defense Agency, AirForce and NASA.

ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study

Retrieved on: 
Wednesday, January 12, 2022
PRV, Forward-looking statement, RECIST, Rhabdomyosarcoma, Patient, Union, American Cancer Society, CEO, TME, ODD, GLOBE, LOS, Sarcoma, Progression-free survival, Tissue, Industry, Marketing, PFS, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, STSS, Company, STS, Mouse, MD, Toxicity, Cancer, Food, Neoplasm, Regulation, FDA, Pharmaceutical industry, Medical imaging

LOS ANGELES, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced study data showing that ImmixBio’s lead candidate IMX-110 produced a 50% response rate in a first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mouse study, surpassing the STS standard of care doxorubicin’s 0% response rate in the same mouse study.   The responses were assessed by RECIST 1.1 criteria applied to mice, with progression assessed after one cycle of treatment in a study funded by ImmixBio and conducted by a major STS oncology treatment center.

Key Points: 
  • (Nasdaq: IMMX) (ImmixBio, Company, We or Us),a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced study data showing that ImmixBios lead candidate IMX-110 produced a 50% response rate in a first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mouse study, surpassing the STS standard of care doxorubicins 0% response rate in the same mouse study.
  • We strive to test our drug candidates in the most realistic, challenging animal models available, said Ilya Rachman, MD PhD, CEO of ImmixBio.
  • We are thrilled to see that in this first-line-therapy resistant STS model that IMX-110 showed significant activity.
  • The U.S. Food and Drug Administration (FDA) has approved orphan drug designation (ODD) for IMX-110 for the treatment of soft tissue sarcoma.